Inmune Bio Stock Performance
| INMB Stock | USD 1.59 0.03 1.92% |
The company retains a Market Volatility (i.e., Beta) of 1.57, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, INmune Bio will likely underperform. At this point, INmune Bio has a negative expected return of -0.0212%. Please make sure to check out INmune Bio's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if INmune Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days INmune Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, INmune Bio is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Acquisition by Ganjei James Kelly of 35000 shares of INmune Bio subject to Rule 16b-3 | 11/13/2025 |
2 | Is INmune Bio Inc. stock positioned for long term growth - 2025 Key Lessons Daily Technical Forecast Reports - newser.com | 11/19/2025 |
3 | Disposition of 160000 shares by Moss David J of INmune Bio at 9.92 subject to Rule 16b-3 | 11/25/2025 |
4 | Inmune Bio Announces New Executive Employment Agreements - TipRanks | 11/28/2025 |
5 | INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595s Evidence Base in High-Inflammation Alzheimers Patients | 12/01/2025 |
6 | Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bios CORDStrom Platform | 12/05/2025 |
7 | Would You Still Hold INmune Bio Stock If It Fell 30 - Trefis | 12/08/2025 |
8 | Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. INMB | 12/12/2025 |
9 | INmune Bio Upgraded at Wall Street Zen | 12/17/2025 |
10 | Aug Wrap How interest rate cuts could boost INmune Bio Inc stock - Quarterly Earnings Summary Real-Time Buy Signal Notifications - moha.gov.vn | 12/22/2025 |
11 | Acquisition by Juda Scott of 150000 shares of INmune Bio at 1.48 subject to Rule 16b-3 | 01/14/2026 |
12 | INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives | 01/27/2026 |
| Begin Period Cash Flow | 35.8 M | |
| Free Cash Flow | -33.4 M |
INmune Bio Relative Risk vs. Return Landscape
If you would invest 172.00 in INmune Bio on November 4, 2025 and sell it today you would lose (13.00) from holding INmune Bio or give up 7.56% of portfolio value over 90 days. INmune Bio is currently does not generate positive expected returns and assumes 4.6234% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than INmune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
INmune Bio Target Price Odds to finish over Current Price
The tendency of INmune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.59 | 90 days | 1.59 | about 71.07 |
Based on a normal probability distribution, the odds of INmune Bio to move above the current price in 90 days from now is about 71.07 (This INmune Bio probability density function shows the probability of INmune Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.57 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, INmune Bio will likely underperform. Additionally INmune Bio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. INmune Bio Price Density |
| Price |
Predictive Modules for INmune Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as INmune Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.INmune Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. INmune Bio is not an exception. The market had few large corrections towards the INmune Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold INmune Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of INmune Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 1.57 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.03 |
INmune Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of INmune Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for INmune Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio may become a speculative penny stock | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14 K. Net Loss for the year was (42.08 M) with profit before overhead, payroll, taxes, and interest of 50 K. | |
| INmune Bio currently holds about 61.21 M in cash with (33.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives |
INmune Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of INmune Stock often depends not only on the future outlook of the current and potential INmune Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. INmune Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.9 M | |
| Cash And Short Term Investments | 20.9 M |
INmune Bio Fundamentals Growth
INmune Stock prices reflect investors' perceptions of the future prospects and financial health of INmune Bio, and INmune Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on INmune Stock performance.
| Return On Equity | -1.56 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (697.24) % | ||||
| Current Valuation | 14.82 M | ||||
| Shares Outstanding | 26.59 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 845.41 X | ||||
| Revenue | 14 K | ||||
| Gross Profit | 50 K | ||||
| EBITDA | (42.08 M) | ||||
| Net Income | (42.08 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 384 K | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 0.95 X | ||||
| Cash Flow From Operations | (33.36 M) | ||||
| Earnings Per Share | (2.11) X | ||||
| Market Capitalization | 42.27 M | ||||
| Total Asset | 39.56 M | ||||
| Retained Earnings | (163.1 M) | ||||
| Working Capital | 15.44 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
About INmune Bio Performance
By analyzing INmune Bio's fundamental ratios, stakeholders can gain valuable insights into INmune Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if INmune Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if INmune Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.64) | (1.73) | |
| Return On Capital Employed | (1.52) | (1.44) | |
| Return On Assets | (0.96) | (1.01) | |
| Return On Equity | (1.51) | (1.43) |
Things to note about INmune Bio performance evaluation
Checking the ongoing alerts about INmune Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for INmune Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio may become a speculative penny stock | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14 K. Net Loss for the year was (42.08 M) with profit before overhead, payroll, taxes, and interest of 50 K. | |
| INmune Bio currently holds about 61.21 M in cash with (33.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives |
- Analyzing INmune Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether INmune Bio's stock is overvalued or undervalued compared to its peers.
- Examining INmune Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating INmune Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of INmune Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of INmune Bio's stock. These opinions can provide insight into INmune Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges |